Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study found that metabolic syndrome is more common in individuals with androgenic alopecia compared to those without, and that free androgen index could help identify those with the syndrome.

This study found that a more liberal intake of restricted amino acids in patients with methylmalonic acidemia resulted in improved growth and fewer illness episodes.

This study found that Atractylodes macrocephala Koidz. extract promotes anagen entry and hair regrowth by enhancing dermal papilla cell activity and supporting hair cycle progression in a mouse model.

This case study of a 2-month-old boy with maple syrup urine disease highlights the dangers of restricting branched-chain amino acid intake, as it led to acrodermatitis dysmetabolica-like skin eruptions and hair loss, later resolved with careful dietary adjustments and monitoring.

This review highlights significant advances in understanding and treating Alopecia Areata, emphasizing the effectiveness of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib for systemic treatment, while also noting ongoing research into new therapeutic approaches such as stem cell therapy and energy-assisted drug delivery.

In this study, the researchers reported that the optimized compound 39 demonstrated potent AR antagonism and favorable pharmacokinetics in a hair-growth mouse model, achieving similar efficacy to pyrilutamide with faster onset and preserved safety, offering promise for next-generation topical AR antagonist development.

This review examines the potential roles of azathioprine and methotrexate in treating alopecia areata, concluding that both can be effective as monotherapy or in combination therapy.

This review details the development and genetic background of senescence-accelerated mouse strains, provides a comprehensive examination of their phenotypes, and highlights their importance for aging research, but reports no new experimental results.

This systematic review reported objective clinical improvement with low-dose oral minoxidil in up to 100% of patients with androgenetic alopecia and up to 82.4% with alopecia areata.

This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.

This study introduced a novel framework that significantly improves the accuracy of alopecia areata lesion segmentation in semi-supervised scenarios, outperforming existing methods and aiding in the disease's diagnosis, treatment, and staging, which can impact quality of life and mental well-being.

This study found that dysregulated microRNA expression in mice may be linked to aberrant gene activity that contributes to the development of alopecia areata.

This study found that ChatGPT 4.0 and Gemini 1.5 Flash provided more accurate and user-friendly responses to androgenetic alopecia questions than Deepseek R1, suggesting they could be effective tools for patient education with physician guidance.

This review identified evidence gaps in NHIRD, emphasizing the lack of validated diagnostic criteria and the need for further research on ocular and systemic comorbidities associated with AA to enhance patient care and treatment strategies.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This research discusses the complex immune pathogenesis of alopecia areata and highlights the success of Jak inhibitors and IL-4Rα antagonists, while IL-17A and PDE4 inhibitors showed limited efficacy; controlled trials are advocated to better understand cytokine involvement.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This study suggests that macrophages, especially CD206+ subsets, play a key role in hair growth induced by squaric acid dibutyl ester, a therapy used for alopecia areata.

In this study, researchers found potential evidence of inducible skin-associated lymphoid tissue (iSALT) in alopecia areata patients undergoing topical immunotherapy, which may suggest an essential role in treatment efficacy.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This review discusses male androgenetic alopecia treatments, noting that topical minoxidil and oral finasteride are FDA-approved and require continuous use to maintain hair retention effects, but reports no new clinical results.

This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.

This study reports the crystallization of the human androgen receptor's ligand-binding domain with nonsteroidal ligands, which may aid in understanding the differences in binding compared to steroidal ligands.

This study found that the addition of SPACE peptide significantly enhanced the penetration of amniotic membrane stem cell metabolites in mice, with only very mild irritation observed.

This review discusses the concept of andropause, preferring the term "androgen decline in the aging male" (ADAM), and emphasizes the need for urologists to recognize its manifestations and manage its treatment, but reports no new clinical results.

In this study, ALR was found to enhance both the proliferation and osteogenic differentiation of mouse bone marrow mesenchymal stem cells, potentially through specific signaling pathways.

This study found that using a vibration anesthetic device during scalp mesotherapy significantly reduced pain in patients with androgenetic alopecia and alopecia areata compared to the non-vibration side.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.